← Back

Harmony Biosciences Holdings

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Price · split & dividend adjusted
News & notes moving HRMY
HRMY▲

Harmony Biosciences Q2 profit climbs to $75.43 million

Harmony Biosciences Holdings reported second-quarter earnings that increased from a year ago. Net income rose to $75.43 million, or $1.28 per share, compared with $39.78 million, or $0.68 per share, in the same period last year. Revenue grew 30.3% to $261.28 million from $200.49 million. The company issued full-year revenue guidance of $1.0 billion to $1.04 billion.
HRMY ▲
RTTNews·22dRead more ▾
HRMY▲2

Zacks Highlights Five Biotech Stocks Poised for Q2 Earnings Beats

Zacks Equity Research has identified five biotech companies that are expected to beat earnings estimates in their upcoming second-quarter 2026 reports. The stocks are Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed, and Agios Pharmaceuticals, each combining a positive Earnings ESP with a Zacks Rank of 1, 2, or 3. Harmony Biosciences carries an Earnings ESP of +14.14% and a Zacks Rank #1, with a consensus estimate of 97 cents per share, and reports on August 4 before the open. Acadia Pharmaceuticals has an Earnings ESP of +25.00% and a Zacks Rank #2, with a consensus of 6 cents per share, reporting after the close on August 4. Biogen shows an Earnings ESP of +220.79% and a Zacks Rank #3, with a consensus of 94 cents per share, and reports on July 29 before the open. Insmed has an Earnings ESP of +22.32% and a Zacks Rank #3, with a consensus loss of 69 cents per share, reporting on August 6 before the open. Agios Pharmaceuticals has an Earnings ESP of +12.67% and a Zacks Rank #3, with a consensus loss of $1.86 per share, and reports on July 30 before the open.
ACAD ▲AGIO ▲BIIB ▲HRMY ▲INSM ▲
Zacks Investment Research·29dRead more ▾
HRMY▲

Harmony Biosciences Preannounces Record Q2 2026 Revenue of $261 Million, Reaffirms $1.0–$1.04 Billion Full-Year Guidance, and Announces CFO Transition

Harmony Biosciences preannounced record quarterly net product revenue for WAKIX of approximately $261 million for the second quarter of 2026, representing 30% year-over-year growth and 21% sequential growth from the first quarter. The company reaffirmed its full-year 2026 net product revenue guidance of $1.0 billion to $1.04 billion, citing strong demand and disciplined commercial execution. Harmony also announced that Chief Financial Officer Glenn Reicin has stepped down effective July 16, 2026, and that Stephen Mollichella, Senior Vice President and Controller, has been appointed Interim Principal Financial Officer. The company stated that Mr. Reicin's departure is not due to any disagreement and does not expect the transition to affect its performance. Full second-quarter 2026 financial results will be reported on August 4, 2026.
HRMY ▲
Business Wire·41dRead more ▾
HRMY▼3

Harmony Biosciences Stock Offers Cheap Valuation but Faces Concentration Risk

Harmony Biosciences Holdings presents a mixed picture for investors, with a cheap valuation offset by heavy reliance on its narcolepsy drug Wakix. The stock trades at 10.38 times forward earnings, well below the Zacks sub-industry average of 44.24 times, and carries a PEG ratio of 0.70. In 2025, net product revenues rose to $868.5 million from $714.7 million a year earlier, and the company reiterated 2026 Wakix revenue guidance of $1.0 billion to $1.04 billion. However, first-quarter 2026 earnings of 55 cents per share missed the Zacks Consensus Estimate of 76 cents, and net product revenues of $215.4 million fell short of the $222 million estimate, partly due to seasonal market access headwinds. The company ended the quarter with about 8,600 patients on therapy and held $870.5 million in cash, cash equivalents and investments. Pipeline progress, including a planned pitolisant GR submission in the second quarter, could re-rate the stock, but the current Zacks Rank of 3 (Hold) and a Momentum Score of D suggest a measured near-term setup.
HRMY ▼
Zacks Investment Research·58dRead more ▾
© 2026 MarketDXAsset